


Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Femara, with the generic name Letrozole, is an oral, non-steroidal aromatase inhibitor. Its primary mechanism of action involves the potent and selective inhibition of the aromatase enzyme, which is responsible for the synthesis of estrogen. By significantly reducing circulating estrogen levels in postmenopausal women, it targets hormone-sensitive pathways that are crucial for the growth and proliferation of certain types of breast cancer cells, forming the basis of its therapeutic application.
Adjuvant Treatment: Postmenopausal women with HR+ early breast cancer.
Extended Adjuvant Treatment: Postmenopausal women with early breast cancer who have completed prior standard adjuvant tamoxifen therapy (typically 5 years).
Advanced/Metastatic Breast Cancer: First- and second-line treatment in postmenopausal women with HR+ or hormone receptor unknown, locally advanced or metastatic disease.
The standard recommended dose is 2.5 mg administered orally once daily, without regard to meals.
